![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Merz Pharmaceuticals GmbH |
---|---|
Information provided by: | Merz Pharmaceuticals GmbH |
ClinicalTrials.gov Identifier: | NCT00739635 |
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
Condition | Intervention | Phase |
---|---|---|
Subjective Tinnitus |
Drug: Neramexane mesylate Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus |
Estimated Enrollment: | 400 |
Study Start Date: | September 2008 |
Estimated Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Neramexane mesylate
Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
|
2: Placebo Comparator |
Drug: Placebo
Double-blind treatment period of 17 weeks placebo
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Clinical R & D CNS ( Janos Csikos, MD ) |
Study ID Numbers: | MRZ 92579/TI/3001, EudraCT Number 2007-007835-16 |
Study First Received: | August 21, 2008 |
Last Updated: | September 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00739635 History of Changes |
Health Authority: | Austria: AGES PharmMed Bundesamt für Sicherheit im Gesundheitswesen; Germany: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)Fachregistratur Z 172; Portugal: INFARMED Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.; Spain: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); UK: MHRA The Clinical Trials Unit, Department of Health |
Signs and Symptoms Sensation Disorders Hearing Disorders Otorhinolaryngologic Diseases |
Neurologic Manifestations Ear Diseases Tinnitus |
Signs and Symptoms Sensation Disorders Hearing Disorders Otorhinolaryngologic Diseases |
Nervous System Diseases Neurologic Manifestations Ear Diseases Tinnitus |